Compare STM & WAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | STM | WAT |
|---|---|---|
| Founded | 1987 | 1958 |
| Country | Netherlands | United States |
| Employees | 49157 | N/A |
| Industry | Semiconductors | Biotechnology: Laboratory Analytical Instruments |
| Sector | Technology | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 60.2B | 33.5B |
| IPO Year | N/A | 1996 |
| Metric | STM | WAT |
|---|---|---|
| Price | $78.19 | $359.82 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 17 |
| Target Price | $47.00 | ★ $379.19 |
| AVG Volume (30 Days) | ★ 11.6M | 842.0K |
| Earning Date | 04-23-2026 | 05-05-2026 |
| Dividend Yield | ★ 0.61% | N/A |
| EPS Growth | N/A | ★ 0.47 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $16.76 | $104.66 |
| Revenue Next Year | $12.40 | $10.40 |
| P/E Ratio | $187.61 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $21.11 | $275.05 |
| 52 Week High | $81.42 | $414.15 |
| Indicator | STM | WAT |
|---|---|---|
| Relative Strength Index (RSI) | 65.08 | 55.18 |
| Support Level | $25.84 | $285.81 |
| Resistance Level | $81.42 | $392.00 |
| Average True Range (ATR) | 3.87 | 12.24 |
| MACD | -0.41 | -1.09 |
| Stochastic Oscillator | 78.35 | 54.00 |
A merger between Italian firm SGS Microelettronica and the nonmilitary business of Thomson Semiconducteurs in France formed STMicroelectronics in 1987. STMicroelectronics is a leader in a variety of semiconductor products, including analog chips, discrete power semiconductors, microcontrollers, and sensors. It is an especially prominent chip supplier to the industrial and automotive industries.
Waters sells liquid chromatography, mass spectrometry, and thermal analysis tools. These analytical instruments provide essential information on various products, such as their molecular structures and physical properties, to help clients enhance the health and well-being of end users. In early 2026, Waters merged with BD's life science and diagnostics business, which increased its concentration in diagnostics (versus none now) and discovery-related life science tools.